Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance

被引：20
作者：
Balch, Curt [1 ,2 ]
Nephew, Kenneth P. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Indiana Univ Sch Med, Bloomington, IN 47405 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA
[3] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA
[4] Indiana Univ Sch Med, Dept Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA
[5] Indiana Univ Sch Med, Dept Cellular & Integrat Physiol, Med Sci Program, Bloomington, IN 47405 USA
来源：
EPIGENETIC ALTERATIONS IN ONCOGENESIS | 2013年 / 754卷
基金：
美国国家卫生研究院;
关键词：
HISTONE DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR GENES; SUBEROYLANILIDE HYDROXAMIC ACID; LOW-DOSE 5-AZA-2'-DEOXYCYTIDINE; BREAST-CANCER CELLS; DNA-HYPOMETHYLATING AGENT; ACUTE MYELOID-LEUKEMIA; PHASE-II TRIAL; EPITHELIAL OVARIAN-CANCER; CISPLATIN PLUS DECITABINE;
D O I：
10.1007/978-1-4419-9967-2_14
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now well established that epigenetic aberrations occur early in malignant transformation, raising the possibility of identifying chemopreventive compounds or reliable diagnostic screening using epigenetic biomarkers. Combinatorial therapies effective for the reexpression of tumor suppressors, facilitating resensitization to conventional chemotherapies, hold great promise for the future therapy of cancer. This approach may also perturb cancer stem cells and thus represent an effective means for managing a number of solid tumors. We believe that in the near future, anticancer drug regimens will routinely include epigenetic therapies, possibly in conjunction with inhibitors of "stemness" signal pathways, to effectively reduce the devastating occurrence of cancer chemotherapy resistance.
引用
收藏
页码：285 / 311
页数：27
相关论文
共 220 条
  • [1] Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells
    Abbosh, Phillip H.
    Montgomery, John S.
    Starkey, Jason A.
    Novotny, Milos
    Zuhowski, Eleanor G.
    Egorin, Merrill J.
    Moseman, Annie P.
    Golas, Adam
    Brannon, Kate M.
    Balch, Curtis
    Huang, Tim H. M.
    Nephew, Kenneth P.
    [J]. CANCER RESEARCH, 2006, 66 (11) : 5582 - 5591
  • [2] Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer
    Aguilera, O.
    Fraga, M. F.
    Ballestar, E.
    Paz, M. F.
    Herranz, M.
    Espada, J.
    Garcia, J. M.
    Munoz, A.
    Esteller, M.
    Gonzalez-Sancho, J. M.
    [J]. ONCOGENE, 2006, 25 (29) : 4116 - 4121
  • [3] Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4
    Ahn, Mee Young
    Chung, Hae Young
    Choi, Wahn Soo
    Lee, Byung Mu
    Yoon, Sungpil
    Kim, Hyung Sik
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) : 125 - 131
  • [4] Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
    Alcazar, Oscar
    Achberger, Susan
    Aldrich, Wayne
    Hu, Zhenbo
    Negrotto, Soledad
    Saunthararajah, Yogen
    Triozzi, Pierre
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (01) : 18 - 29
  • [5] ANZAI H, 1992, CANCER RES, V52, P2180
  • [6] Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors
    Appleton, Kim
    Mackay, Helen J.
    Judson, Ian
    Plumb, Jane A.
    McCormick, Carol
    Strathdee, Gordon
    Lee, Chooi
    Barrett, Sophie
    Reade, Sarah
    Jadayel, Dalal
    Tang, Adrian
    Bellenger, Katharine
    Mackay, Lynsay
    Setanoians, Albert
    Schaetzlein, Andreas
    Twelves, Chris
    Kaye, Stanley B.
    Brown, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4603 - 4609
  • [7] Genomic DNA Hypomethylation by Histone Deacetylase Inhibition Implicates DNMT1 Nuclear Dynamics
    Arzenani, Mohsen Karimi
    Zade, Atosa Esteki
    Ming, Yu
    Vijverberg, Susanne J. H.
    Zhang, Zhe
    Khan, Zahidul
    Sadique, Syed
    Kallenbach, Lorenz
    Hu, LiFu
    Vukojevic, Vladana
    Ekstrom, Tomas J.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (19) : 4119 - 4128
  • [8] AVRAMIS VI, 1989, CANCER CHEMOTH PHARM, V24, P203
  • [9] Antimitogenic and chernosensitizing effects of the methylation inhibitor zebularine in ovarian cancer
    Balch, C
    Yan, P
    Craft, T
    Young, S
    Skalnik, DG
    Huang, THM
    Nephew, KP
    [J]. MOLECULAR CANCER THERAPEUTICS, 2005, 4 (10) : 1505 - 1514
  • [10] New anti-cancer strategies: Epigenetic therapies and biomarkers
    Balch, C
    Montgomery, JS
    Paik, HI
    Kim, S
    Huang, THM
    Nephew, KP
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 : 1897 - 1931
12345678910